← Back to Search

Adult patients with CML in chronic phase (CML-CP) for Chronic Myelogenous Leukemia

N/A
Recruiting
Led By Mahtab Jafari, Pharm.D
Research Sponsored by University of California, Irvine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights

Study Summary

This is an observational pilot study to examine the association between a patient's personality and adherence to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

Eligible Conditions
  • Chronic Myelogenous Leukemia
  • Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Assessment of adherence to TKI medication
Assessment of quality of Life
Assessment of quality of Life and symptom burden
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Adult patients with CML in chronic phase (CML-CP)Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

University of California, IrvineLead Sponsor
544 Previous Clinical Trials
1,922,968 Total Patients Enrolled
Mahtab Jafari, Pharm.DPrincipal InvestigatorChao Family Comprehensive Cancer Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~50 spots leftby Dec 2024